Sociodemographic Factors Affect Prostate CA Treatment Initiation

This article originally appeared here.
Share this content:
Sociodemographic Factors Affect Prostate CA Treatment Initiation
Sociodemographic Factors Affect Prostate CA Treatment Initiation

THURSDAY, Aug. 18, 2016 (HealthDay News) -- For men with low-risk prostate cancer undergoing active surveillance, sociodemographic factors are associated with initiation of active treatment, according to a study published in the September issue of The Journal of Urology.

Scott P. Kelly, Ph.D., from the Georgetown University Medical Center in Washington, D.C., and colleagues conducted a retrospective study of men diagnosed with low-risk prostate cancer between 2004 and 2012 who did not receive any treatment within the first year of diagnosis. Patients were followed for at least two years to determine the factors associated with time from diagnosis to active treatment.

The researchers identified 2,228 eligible men, of whom 27 percent began active treatment at a median of 2.9 years. Independent of baseline and follow-up clinical measures, non-Hispanic black men were slightly more likely to begin active treatment than non-Hispanic white men (hazard ratio [HR], 1.3; 95 percent confidence interval [CI], 1.0 to 1.7). Of those men who remained on observation, the rate of rebiopsy within 24 months of diagnosis was slightly lower for non-Hispanic black men than non-Hispanic white men (HR, 0.70; 95 percent CI, 0.6 to 1.0). Independent of race, initiation of active treatment was associated with Gleason grade progression (HR, 3.3; 95 percent CI, 2.7 to 4.1) and prostate-specific antigen doubling time less than 48 months (HR, 2.9; 95 percent CI, 2.3 to 3.7).

"Sociodemographic factors such as ethnicity and education may independently influence the patient decision to pursue active treatment and serial biopsies during active surveillance," the authors write. "These factors are important for further studies of prostate cancer treatment decision making."

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »